Clene Inc.
NASDAQ:CLNN
Overview | Financials
Company Name | Clene Inc. |
Symbol | CLNN |
Currency | USD |
Price | 4.8 |
Market Cap | 38,302,704 |
Dividend Yield | 0% |
52-week-range | 3.82 - 11 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Robert Etherington MBA |
Website | https://clene.com |
An error occurred while fetching data.
About Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD